GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
GlycoMimetics (GLYC) Tops Q2 EPS by 8c
November 7, 2019 8:26 AM ESTGlycoMimetics (NASDAQ: GLYC) reported Q2 EPS of ($0.31), $0.08 better than the analyst estimate of ($0.39).
In the third quarter of 2019, we continued to progress the late-stage clinical development of our wholly-owned product candidate, uproleselan. Our Company-sponsored Phase 3 trial in relapsed or refractory AML patients and the NCI-sponsored Phase 3 trial for newly diagnosed patients with AML both advanced during the quarter. We are also working with the Duke Cancer Institute towards... More
